Corbus Pharmaceuticals Holdings Inc Stock

$4.82

7.31% today

Nasdaq, Apr 03, 06:42 pm CET

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Corbus Pharmaceuticals Holdings Inc Stock price

$5.20

-141.50 96.46% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

+0.17 3.38%

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$63.61m
Enterprise Value	$-82.50m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.97
P/B ratio (TTM) P/B ratio	0.44
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-48.72m
Free Cash Flow (TTM) Free Cash Flow	$-41.79m
Cash position	$149.35m
EPS (TTM) EPS	$-3.66
P/E forward	negative
P/S forward	31.81
EV/Sales forward	negative
Short interest	25.16%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.70 0.70	15% 15% -
Gross Profit	-0.70 -0.70	15% 15% -
- Selling and Administrative Expenses	15 15	23% 23% -
- Research and Development Expense	32 32	3% 3% -
EBITDA	-48 -48	9% 9% -
- Depreciation and Amortization	0.70 0.70	15% 15% -
EBIT (Operating Income) EBIT	-49 -49	8% 8% -
Net Profit	-40 -40	10% 10% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Corbus Pharmaceuticals Holdings Inc Stock News

Neutral

GlobeNewsWire

●

6 days ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being ...

Neutral

GlobeNewsWire

●

about 2 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Neutral

GlobeNewsWire

●

about 2 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 20...

More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office	United States
CEO	Yuval Cohen
Employees	28
Founded	2009
Website	www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now